Blood test may improve cancer care for colorectal and lung cancer patients

NCT ID NCT04258137

Ongoing Knowledge-focused Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study is testing whether regular blood tests that look for tumor DNA (called liquid biopsy) can help doctors make better treatment decisions for people with advanced colorectal or lung cancer. About 332 participants will be randomly assigned to either receive standard imaging follow-up or imaging plus liquid biopsy. The goal is to see if the extra blood test information leads to longer survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liquid biopsy (ctDNA)
What this could lead to: If successful, this could show that regular ctDNA testing helps doctors choose better treatments and monitor cancer more accurately, potentially improving survival.
What could go wrong: This is a phase 2 trial with a small number of participants, so results may not apply to all patients. The benefit of ctDNA over standard imaging is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

CHRU Brest

Brest, 29200, France
Centre hospitalier de la Côte Basque

Bayonne, 64109, France
Clinique Tivoli-Ducos

Bordeaux, 33000, France
Institut Bergonie

Bordeaux, 33076, France
Polyclinique Bordeaux Nord Aquitaine

Bordeaux, 33077, France
Polyclinique Marzet

Pau, 64000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.